Profile picture

Doctor Taijyu Satoh

Tohoku University Hospital, Sendai (Japan)
Follow
Biography
My ultimate career goal has been to become an independent scientist in the cardiovascular biology. The extensive training during my pursuit of Ph.D. degree in Tohoku University in Japan equipped me with the knowledge and skill to explore the new finding of cardiovascular pathophysiology. During my doctoral research, I focused on the pathogenesis of CTEPH. We reported that TAFI is activated in patients with CTEPH and PH model mice and rats. Importantly, TAFI-overexpressing promoted clot formation and multiple PA obstruction. After that, I started my postdoctoral research abroad at the University of Pittsburgh in 2018. Under the mentorship of Prof. Mark T. Gladwin, my basic research currently focuses on finding new mechanism of Exercise-Induced Pulmonary Hypertension (EIPH) in Heart Failure with preserved Ejection Fraction (HFpEF). We hypothesize that metabolic syndrome and oxidation of soluble guanylate cyclase β1 subunit contributes to pulmonary artery dysfunction in EIPH in HFpEF.
Logo ESC

Contributor content

New treatment strategies based on the pathophysiology of Group 2 pulmonary hypertension
Presentation
New treatment strategies based on the pathophysiology of Group 2 pulmonary hypertension
Hypopituitarism induced by continuous infusion of PGI2 analogues
Presentation
Hypopituitarism induced by continuous infusion of PGI2 analogues
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
Presentation
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-
Presentation
Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-

ESC 365 is supported by